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Selective COX-2 inhibitors are non-steroidal anti-inflammatory drugs which directly target 
cyclooxygenase-2 (COX-2), an enzyme mainly responsible for induction of inflammation, pyresis and 
pain. Although commonly used in avian medicine, limited pharmacokinetic (PK) data in domestic and 
companion birds are available. In this study, PK parameters and absolute oral bioavailability expressed 
as percentage (F%) of celecoxib (10 mg/kg BW), mavacoxib (4 mg/kg BW) and meloxicam (1 mg/kg 
BW) were determined following single oral (PO) and intravenous (IV) administration to cockatiels 
(Nymphicus hollandicus). The drugs were quantified in plasma by liquid chromatography-tandem mass 
spectrometry. Data were processed using the nonlinear mixed effects (NLME) approach. In contrast to 
celecoxib (T1/2el = 0.88 h) and meloxicam (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life 
(T1/2el = 135 h) following oral administration of a commercial formulation (CF). High to complete oral 
absorption was observed following oral administration of celecoxib (F% = 56–110%) and mavacoxib 
(F% = 111–113%), CF and standard solutions, respectively. In contrast, the F% of meloxicam was low 
(F% = 11%). Based on the presented results, a less frequent dosing of mavacoxib is proposed compared 
to celecoxib and meloxicam. However, pharmacodynamic and safety studies are necessary to further 
investigate the use of these NSAIDs in cockatiels.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in both veterinary and human medicine 
for their anti-inflammatory, analgesic and antipyretic properties. NSAIDs prevent conversion of arachidonic acid 
into prostanoids, including prostaglandins, prostacyclins and thromboxanes, by inhibiting the cyclooxygenase 
(COX) iso-enzymes. Two related isoforms of the COX enzyme have been described: cyclooxygenase-1 (COX-1) 
and cyclooxygenase-2 (COX-2). COX-1 is constitutively expressed in several tissues and is involved in the regula-
tion of homeostatic functions throughout the body. In contrast, the expression of COX-2 is generally considered 
to be induced by inflammatory stimuli under different pathological conditions. However, in certain tissues like 
the kidney, brain and thymus, COX-2 is also constitutively expressed1–3. COX-1 and COX-2 are both targets 
of non-selective NSAIDs, whereas COX-2 selective NSAIDs inhibit selectively COX-2. These selective COX-2 
inhibitors cause less side effects by preserving the COX-1 regulated homeostatic functions, including gastric 
cytoprotection, renal blood flow maintenance and platelet function3–5.
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Avian pain management is characterized by multiple challenges. Recognizing pain and assessing its intensity 
are both essential for effective management. However, behaviour associated with painful stimuli is often subtle 
and not very specific in birds. Consequently, failure to appreciate the intensity of pain will confine the selection 
of an appropriate potent analgesic drug and corresponding dosing regimen6. Therefore, both owners and clini-
cians must be familiar with the normal behaviour of both the animal species and the individual bird to recognize 
signs of pain7,8. Secondly, pharmacokinetic (PK) processes of drugs, namely absorption, distribution, metabolism 
and excretion (ADME), differ largely between mammals and birds, and they also vary among avian species. 
Significant species differences in the primary PK properties of some NSAIDs, such as salicylic acid, flunixin, 
and meloxicam, show that PK data and also posology, can hardly be extrapolated from mammals to birds and 
among different bird species8–10. Third, the safety profile of NSAIDs may vary considerably among animal species, 
including birds11,12.
Notwithstanding these considerations, NSAIDs are commonly used in avian clinical practice to reduce 
pain and inflammation of various origins, including musculoskeletal, visceral and postoperative pain. Various 
NSAIDs, like meloxicam, piroxicam, carprofen, ketoprofen and celecoxib, have been used in birds to treat pain 
and inflammation, with meloxicam (Fig. 1a) as preferential COX-2 inhibitor being the most widely used in avian 
practice8,13,14. However, the usage is off-label. Meloxicam has been used in a dose range of 0.1–2.0 mg/kg body 
weight (BW) for various painful and/or inflammatory conditions, like arthritis, postoperative pain and proven-
tricular dilatation disease (PDD)15. PDD is a progressive, infectious neurologic disease, mainly affecting psittacine 
birds. It is characterized by an avain bornavirus-induced inflammation of the digestive tract as well as the central 
and peripheral nervous system. This inflammation leads to a variability of clinical signs such as weight loss, crop 
stasis, regurgitation, maldigestion, and eventually starvation and death16,17. Since inflammation is the key patho-
logic event, NSAIDs may have a therapeutic value in the symptomatic treatment of PDD. PK studies conducted 
in several avian species showed a wide interspecies variability in PK properties of meloxicam. Significant PK 
variations between chickens (Galllus gallus), ostriches (Struthio camelus), ducks (Anas platyrhynchos), turkeys 
(Meleagris gallopavo), pigeons (Columba livia), Hispaniolan Amazon parrots (Amazona ventralis) and African 
grey parrots (Psittacus erithacus) have been reported. Divergent values of clearance (Cl) and volume of dis-
tribution (Vd) were observed in these species, ranging from 2.18 to 720 mL/h.kg and 58 to 580 mL/kg respec-
tively10,15,18. Furthermore, allometric scaling showed poor correlations between BW and these PK parameters in 
different avian species10.
The coxibs, such as celecoxib and mavacoxib, have a highly specific action on the COX-2 enzyme. In humans, 
celecoxib (Fig. 1b) is indicated in case of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute 
pain. Its use in veterinary medicine is off-label, however, celecoxib in a dose of 10 mg/kg BW is used in clinical 
practice for the symptomatic treatment of PDD in birds. Although no peer-reviewed studies about the use of 
celecoxib in case of PDD are available, it is considered as the standard therapy. Mavacoxib (Fig. 1c), registered for 
use in dogs with osteoarthritis, is characterized by a metabolically stable fluoro substituent at the position were 
its structural analogue celecoxib has a metabolically labile aromatic methyl group. Consequently, in dogs a low 
clearance and prolonged elimination half-life (t1/2el) are reported. Therefore a less frequent dosing is necessary, 
which contributes to an improved therapeutic compliance19–21. Initially, a classical dose determination study indi-
cated that a dose of 4 mg/kg BW is necessary to exhibit clinical efficacy. More recently, population PK (popPK) 
data showed that reducing the dose from 4 mg/kg BW to 2 mg/kg BW in combination with a non-constant dosing 
interval (2 weeks between the first two doses; thereafter maintenance interval of 4 weeks) was sufficient to attain 
and maintain therapeutic concentrations19,22. To date, no information on the use of mavacoxib in avian species 
has been described in literature.
The purpose of this study was first to develop and validate a sensitive and specific liquid chromatography-tandem 
mass spectrometric (LC-MS/MS) method for quantification of meloxicam, celecoxib and mavacoxib in avian 
plasma. Second, the PK properties and absolute oral bioavailability of celecoxib, mavacoxib and meloxicam in cock-
atiels (Nymphicus hollandicus) after single intravenous (IV) and oral (PO) administration using a popPK approach 
were assessed.
Results
LC-MS/MS methods. Linear matrix-matched calibration curves, covering a concentration range of 5–5000 
ng/mL (celecoxib and mavacoxib) and 10–5000 ng/mL (meloxicam), were obtained. Good correlation between 
analyte concentrations and detected responses was demonstrated for all compounds, with correlation coefficient 
Figure 1. Molecular structure of meloxicam (a) celecoxib (b) and mavacoxib (c).
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(r) values ranging between 0.9982 and 0.9999 and goodness-of-fit coefficient (gof) values between 4.95 and 6.25% 
(see Supplementary Table S1). The acceptance criteria for within- and between-run accuracy and precision were 
met for all drugs at the specified concentration levels (see Supplementary Table S2). The limits of quantifica-
tion (LOQ) were 5 ng/mL for celecoxib and mavacoxib, and 10 ng/mL for meloxicam. The calculated limit of 
detection (LOD) values, corresponding with a signal/noise (S/N) ratio of 3, were 0.22, 0.25 and 0.18 ng/mL 
for celecoxib, mavacoxib and meloxicam, respectively (see Supplementary Table S1). Since no interfering peaks 
could be detected in any of the blank samples at the retention time of the drugs, the specificity of the method was 
demonstrated. No carry-over was present as there was no analyte detected in the solvent sample injected after the 
highest calibrator.
Pharmacokinetic analysis. During the animal experiment no clinical signs of toxicity were observed in 
any of the birds. All birds were alert, had a normal feed intake and normal droppings, and no regurgitation was 
observed. Plasma drug concentration-time profiles of celecoxib, mavacoxib and meloxicam are shown in Figs 2, 3 
and 4, respectively. PopPK results are presented in Tables 1, 2 and 3. For the oral CF of celecoxib and meloxicam, 
a lag-time was included since this significantly improved the model fit. The evaluated covariates, BW and gender, 
were not significant for addition to the PK models for any of the drugs. Inclusion of enterohepatic recircula-
tion (EHR) in the model of meloxicam did not significantly improve the model fit (−2 log likelihood (−2LL), 
Akaike’s information criterion (AIC) and Bayesian information criterion (BIC)) (Table 4). Although EHR has 
been demonstrated for several animal species, this lack of improvement is most probably attributed to the limited 
blood collection points at the secondary plasma concentration peak. Visual inspection of the goodness-of-fit plots 
of the individual model-predicted concentrations (IPRED) versus the observed concentrations (Cobs) revealed an 
appropriate structural model for most individuals. The quantile-quantile (QQ) plots of the conditionally weighted 
residuals of Cobs demonstrated normal distribution of the weighted residuals (see Supplementary Fig. S1–S3).
The absolute oral bioavailability expressed as percentage (F%) of celecoxib was 110% and 56%, standard solu-
tion (STD) and commercial formulation (CF), respectively. For mavacoxib, F% was 113% (STD) and 111% (CF). 
The F% of meloxicam, when EHR was not taken into account, was 11%. Vd and Cl after oral administration 
were corrected for the absolute oral bioavailability and were in most cases similar between the different routes 
of administration and formulations. Because of that similarity and to reduce the complexity of the paper, mainly 
IV data is further provided. Important differences in PK parameters were observed when comparing the three 
NSAIDs following IV administration. In contrast to meloxicam (0.173 L/kg), the observed Vd of the coxibs, cel-
ecoxib (4.67 L/kg) and mavacoxib (10.99 L/kg), were high. Although the strong structural relationship, mavacoxib 
had a larger Vd than celecoxib. Due to its metabolic resistance, mavacoxib (0.036 L/h.kg) possesses a remarkably 
low Cl. The observed Cl of celecoxib (2.42 L/h.kg) is higher than meloxicam (0.388 L/h.kg). As a result of the 
combination of a high Vd and low Cl the T1/2el of mavacoxib (212 h) exceeded to a considerable degree the T1/2el of 
celecoxib (1.34 h) and meloxicam (0.31 h).
Plasma protein binding (mean ± SD) was high, namely 98.98 ± 0.07%, 97.02 ± 0.32% and 95.02 ± 0.01% for 
celecoxib, mavacoxib and meloxicam, respectively.
Discussion
For the first time, a comparative study was performed to evaluate the PK of three different COX 2 inhibi-
tors, celecoxib, mavacoxib and meloxicam, in cockatiels (Nymphicus hollandicus) as a model for the order of 
Psittaciformes. Besides, cockatiels are frequently used as model in PDD studies. The doses of celecoxib (10 mg/kg 
Figure 2. Pharmacokinetic profiles of celecoxib. Observed and modeled plasma concentration-time profiles of 
celecoxib (10 mg/kg BW) after IV (n = 34) (a) and PO (n = 34) (b) administration of the standard solution and 
of the PO administration of the commercial formulation (n = 22) (c) in cockatiels.
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BW), mavacoxib (4 mg/kg BW) and meloxicam (1 mg/kg BW) used in the present study were based on previous 
literature reports15,19. Since a large number of samples need to be analysed in PK studies, high-throughput sample 
preparation is crucial. The application of the OstroTM 96-well plate for meloxicam and liquid-liquid extraction for 
celecoxib and mavacoxib is straightforward and relatively quick to perform. The combination of these robust sam-
ple preparation methods with LC-MS/MS allows a sensitive and selective quantification of celecoxib, mavacoxib 
and meloxicam in avian plasma. The presented results of the different PK parameters of the selected NSAIDs are 
opening perspectives for clinical use in birds, although further specific pharmacodynamic and safety studies are 
necessary. Given the limited blood volume in cockatiels, a sparse sampling protocol was applied which renders 
popPK modelling using non-linear mixed-effects (NLME) analysis necessary. The application of popPK model-
ling offers the possibility to collect representative samples while minimizing distress and blood loss, which is of 
pivotal importance in small and exotic bird species23. Complete drug absorption was demonstrated following oral 
administration of mavacoxib STD and CF (F% = 113 and 111%, respectively). In contrast, the F% of celecoxib 
after CF administration (56%) was notably lower than after STD administration (110%). A remarkable finding 
was the considerable low F% of meloxicam (11%). Although the oral formulations differed between the cited 
studies, or no details on the formulations were given, generally a high F% is reported for meloxicam in humans 
(89–97%)24,25 and in other mammals (85–106%)26–28. In contrast, the limited PK studies described in avian spe-
cies, using the same oral formulation (Metacam oral suspension®, Boehringer Ingelheim) as used in this study, 
demonstrate a highly variable interspecies F%, ranging from 38% to 74%15,18,29. A possible explanation for these 
differences between avian species, could be the variability in pH values of their proventriculus15,30. In dogs, the 
Figure 3. Pharmacokinetic profiles of mavacoxib. Observed and modeled plasma concentration-time profiles 
of mavacoxib (4 mg/kg BW) after IV (n = 40) (a) and PO (n = 40) (b) administration of the standard solution 
and of the PO administration of the commercial formulation (n = 26) (c) in cockatiels. The insert shows the first 
24 h of the plasma-concentration-time profiles.
Figure 4. Pharmacokinetic profiles of meloxicam. Observed data and modeled plasma concentration-time 
profiles of meloxicam (1 mg/kg BW) after IV (n = 24) (a) and PO (n = 24) (b) administration of the commercial 
formulation in cockatiels.
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F% of celecoxib and mavacoxib is influenced to a large extent by the feeding status of the animal. Presence of food 
was shown to increase oral bioavailability of both drugs19,31. Although in humans, no food effects on the F% of 
celecoxib were observed31. Since higher F% is seen in dogs with food, also in this study feed (2 mL intra-crop feed 
bolus by oral gavage) was co-administered. Further research is necessary to evaluate the impact of feed on F% of 
celecoxib, mavacoxib and meloxicam in avian species.
All three NSAIDs, evaluated in this study, are highly bound to plasma proteins (>95%). In general, extensive 
plasma protein binding typically leads to small Vd. The Vd of meloxicam after IV administration was indeed low 
(0.173 L/kg), which was consistent with the observed high plasma protein binding. In contrast, celecoxib (4.67 L/
kg) and mavacoxib (10.99 L/kg) display a high Vd, despite being highly bound to plasma proteins. Similar effects 
were observed in dogs. Although extensively bound to plasma proteins (>98%), a Vd of 1.82–1.98 L/kg for cel-
ecoxib and 1.41–1.87 L/kg for mavacoxib were observed in dogs19,31,32. These observations may be related to the 
lipophilic nature of these drugs or the type of protein binding.
For mavacoxib and meloxicam, EHR has been described in literature19,21,26,33,34. The present study was not able to 
demonstrate a pronounced presence of EHR in cockatiels, possibly due to the limited blood collection points at the 
secondary peaks. However, the presence of EHR cannot be excluded. In accordance with dogs (Cl = 2.7 mL/h.kg)19, 
mavacoxib after IV administration in cockatiels is also characterized by a very low Cl (0.036 L/h.kg). Due to the 
combination of this low Cl with a relatively large Vd, mavacoxib has a remarkably long plasma T1/2el exceeding 
5 days. For mavacoxib, a prolonged therapeutic effect could be obtained requiring less frequent dosing as is the 
case in dogs (T1/2el = 17.3 days; τ = 2 weeks between first two doses, thereafter 4 weeks). This is an interesting 
Adm. Route Θ Tvθ CV (%) ω
IV STD
Vd (L/kg) 4.67 8.06 <0.001
Cl (L/h.kg) 2.42 7.93 0.0418
C0 (ng/mL) 2141.54 8.06 /
AUC0-inf (ng.h/mL) 4140.36 7.93 /
Ke (h−1) 0.52 5.40 /
T1/2el (h) 1.34 5.40 /
Res. Error 0.42 12.32 /
PO STD
Vd/F (L/kg) 5.87 17.43 0.948
Cl/F (L/h.kg) 2.19 17.86 0.707
Ka (h−1) 0.27 8.98 0.063
T1/2a (h) 2.51 8.98 /
Cmax (ng/mL) 535.51 10.95 /
Tmax (h) 3.11 14.09 /
AUC0-inf (ng.h/mL) 4573.68 17.56 /
Ke (h−1) 0.37 24.38 /
T1/2el (h) 1.86 1.86 /
Res. Error 8.02 34.93 /
PO CF
Vd/F (L/kg) 5.49 25.02 <0.001
Cl/F (L/h.kg) 4.32 11.67 0.055
Tlag (h) 0.33 39.55 0.207
Ka (h−1) 0.39 17.37 <0.001
σmult 0.41 18.17 /
T1/2a (h) 1.76 17.37 /
Cmax (ng/mL) 454.97 14.27 /
Tmax (h) 2.09 8.97 /
AUC0-inf (ng.h/mL) 2312.24 11.67 /
Ke (h−1) 0.79 29.30 /
T1/2el (h) 0.88 29.31 /
Res. Error 15.18 35.72 /
Table 1. Population pharmacokinetic results of intravenous (IV) and oral (PO) administration of celecoxib 
(10 mg/kg BW) to cockatiels using a sparse sampling protocol. STD: analytical standard; CF: commercial 
formulation; Θ: fixed effect parameter; tvθ: population typical value of the fixed effect parameter; CV%: 
coefficient of variation; ω: variance of the interindividual variability (only for fixed parameters); Vd: volume of 
distribution; Cl: total body clearance; C0: plasma concentration at time 0 following IV administration; AUC0-inf:  
area under the plasma concentration-time curve from time 0 to infinity; Ke: elimination rate constant; T1/2el: 
elimination half-life; Res. Error: residual error; Vd/F: volume of distribution uncorrected for absolute oral 
bioavailability; Cl/F: total body clearance uncorrected for absolute oral bioavailability; Ka: absorption rate 
constant; T1/2a: absorption half-life; Cmax: maximal plasma concentration; Tmax: time to maximal plasma 
concentration; Tlag: lag time for absorption following oral administration; σmult: variance of the multiplicative 
residual error.
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result, since for many drugs the correlation between dogs and birds is lacking. For example, cefovecin, a third 
generation cephalosporin, has a long elimination half-life in dogs (T1/2el = 5.5 days)35 whereas the elimination 
half-life in hens is very short (T1/2el = 0.9 h)36, suggesting a completely different posology. Although celecoxib 
and mavacoxib are strongly related structurally, celecoxib has a considerably higher plasma clearance (2.42 L/h.
kg) which results in a relatively short T1/2el of 1.34 h. For meloxicam, a higher value of Cl (0.388 L/h.kg) and cor-
responding shorter T1/2el (0.31 h) after IV administration were obtained in cockatiels in comparison with other 
Psittaciformes (African grey parrots (Cl = 0.00218 L/h.kg; T1/2el = 31.4 h) and Amazon parrots (Cl = 0.0122 L/h.
kg; T1/2el = 15.9 h))15,18. These observations highlight the significant differences in PK of meloxicam for avian spe-
cies, as previously observed by Baert et al.10. Therefore, the PK needs to be evaluated in every target bird species 
to assure an appropriate selection of dosing regimen. Since PK, pharmacodynamics (PD) and drug safety profiles 
are often only available for a limited number of bird species, dose extrapolation between different avian species 
might be performed in veterinary practice based on the correlation of PK characteristics and BW. However, it is 
obvious that this should be done with caution9,37. In some cases, like meloxicam, previous research demonstrated 
that dose extrapolation is not a suitable method for dose determination in avian species10.
In avian species, establishing suitable dosing regimens is not straightforward. To date, there is insufficient 
knowledge about effective plasma concentrations of celecoxib, mavacoxib and meloxicam in bird species. For 
meloxicam, several PK studies have been conducted in birds, including chickens, ostriches, ducks, turkeys, 
pigeons, Hispaniolan Amazon Parrots and African grey parrots10,15,18. Information on the pharmacodynamics of 
meloxicam in birds is however relatively scarce. Cole et al. demonstrated that meloxicam administered at 1.0 mg/
kg IM every 12 hours is significantly more effective than lower dosages in relieving arthritic pain in Hispaniolan 
parrots38. Hoppes et al. investigated the effect of meloxicam treatment in cockatiels infected with avian borna-
virus. In contrast to the expectations, these authors have observed that the combination of avian bornavirus 
challenge and meloxicam (Metacam oral suspension® (Boehringer Ingelheim), 0.5 mg/kg, orally, twice daily for 
Adm. Route Θ Tvθ CV (%) ω
IV STD
Vd (L/kg) 10.99 5.51 0.075
Cl (L/h.kg) 0.036 12.16 0.524
C0 (ng/mL) 363.75 5.51 /
AUC0-inf (ng.h/mL) 111238.0 12.16 /
Ke (h−1) 0.0033 13.55 /
T1/2el (h) 211.97 13.55 /
Res. Error 0.26 13.74 /
PO STD
Vd/F (L/kg) 7.85 4.26 0.006
Cl/F (L/h.kg) 0.031 10.80 0.260
Ka (h−1) 0.20 14.80 0.171
T1/2a (h) 3.48 14.80 /
Cmax (ng/mL) 469.69 3.35 /
Tmax (h) 19.98 10.19 /
AUC0-inf (ng.h/mL) 126108.0 10.80 /
Ke (h−1) 0.0040 12.44 /
T1/2el (h) 171.68 12.44 /
Res. Error 0.29 14.40 /
PO CF
Vd/F (L/kg) 6.35 0.19 0.090
Cl/F (L/h.kg) 0.033 1.35 0.252
Ka (h−1) 0.28 9.97 0.992
T1/2a (h) 2.44 9.97 /
Cmax (ng/mL) 584.66 0.32 /
Tmax (h) 14.42 7.94 /
AUC0-inf (ng.h/mL) 122962.0 1.35 /
Ke (h−1) 0.0051 1.16 /
T1/2el (h) 135.41 1.17 /
Res. Error 0.28 39.64 /
Table 2. Population pharmacokinetic results of intravenous (IV) and oral (PO) administration of mavacoxib 
(4 mg/kg BW) to cockatiels using a sparse sampling protocol. STD: analytical standard; CF: commercial 
formulation; Θ: fixed effect parameter; tvθ: population typical value of the fixed effect parameter; CV%: 
coefficient of variation; ω: variance of the interindividual variability (only for fixed parameters); Vd: volume of 
distribution; Cl: total body clearance; C0: plasma concentration at time 0 following IV administration; AUC0-inf:  
area under the plasma concentration-time curve from time 0 to infinity; Ke: elimination rate constant; T1/2el: 
elimination half-life; Res. Error: residual error; Vd/F: volume of distribution uncorrected for absolute oral 
bioavailability; Cl/F: total body clearance uncorrected for absolute oral bioavailability; Ka: absorption rate 
constant; T1/2a: absorption half-life; Cmax: maximal plasma concentration; Tmax: time to maximal plasma 
concentration.
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130 days) resulted in clinical disease and death, whereas animals solely receiving meloxicam or an ABV chal-
lenge alone remained clinically healthy until the end of the study. However, it is questionable whether effective 
plasma concentration at the used dose regimen (0.5 mg/kg; twice daily) were reached, since the presented study 
revealed a high clearance (0.388 L/h.kg) and remarkably low F% (11%) in cockatiels in comparison with other 
Psittaciformes. Furthermore, only a limited number (12 birds in total) of birds were included in this study. A large 
scale investigation is needed in order to evaluate the reproducibility of these results and, if necessary, to unravel 
the underlying mechanism of the observed difference39. For mavacoxib, plasma concentrations of 0.4 µg/mL were 
associated with efficacy in osteoarthritic dogs20. After single dose PO and IV mavacoxib administration (4 mg/
kg BW) in cockatiels current study demonstrates that plasma concentrations of 0.4 µg/mL were always reached. 
However, a major issue is whether effective plasma concentrations are the same in different animal species and 
clinical conditions. There is a need for more PK-PD studies in order to determine the effective plasma concen-
tration and dose regimen in avian species for each clinical condition. In addition, Cox et al. demonstrated that 
mavacoxib exhibited a dose proportional pharmacokinetics for single oral doses of 2–12 mg/kg in Beagle dogs19. 
Adm. Route Θ Tvθ CV (%) ω
IV CF 1
Vd (L/kg) 0.173 11.74 <0.001
Cl (L/h.kg) 0.388 10.19 0.089
C0 (ng/mL) 5775.52 11.75 /
AUC0-inf (ng.h/mL) 2575.66 10.19 /
Ke (h−1) 2.24 8.74 /
T1/2el (h) 0.31 8.74 /
Res. Error 0.39 26.43 /
IV CF2
Vd (L/kg) 0.148 10.15 <0.001
Cl (L/h.kg) 0.383 9.81 0.113
Ka (h−1) 7.35 18.23 0.020
K1g (h−1) 0.40 31.43 1.153
τ (h) 0.62 9.30 <0.001
C0 (ng/mL) 385.515 10.15 /
AUC0-inf (ng.h/mL) 149.05 9.81 /
Res. Error 0.36 22.79 /
PO CF1
Vd/F (L/kg) 4.40 27.97 <0.001
Cl/F (L/h.kg) 3.38 18.82 0.122
Tlag (h) 0.23 8.60 <0.001
Ka (h−1) 1.19 55.88 1.075
T1/2a (h) 0.58 55.88 /
Cmax (ng/mL) 102.31 19.12 /
Tmax (h) 1.27 17.32 /
AUC0-inf (ng.h/mL) 295.26 18.81 /
Ke (h−1) 0.77 32.34 /
T1/2el (h) 0.90 32.34 /
Res. Error 1.15 14.19 /
Table 3. Population pharmacokinetic results of intravenous (IV) and oral (PO) administration of meloxicam 
(1 mg/kg BW) to cockatiels using a sparse sampling protocol. CF: commercial formulation, 1no enterohepatic 
recycling included in the model; ²with enterohepatic recycling inclusion in the model; Θ: fixed effect parameter; 
tvθ: population typical value of the fixed effect parameter; CV%: coefficient of variation; ω: variance of the 
interindividual variability (only for fixed parameters); Vd: volume of distribution; Cl: total body clearance; 
Ka: absorption rate constant; K1g: bile excretion rate; τ: bile excretion interval; C0: plasma concentration at 
time 0 following IV administration; AUC0-inf: area under the plasma concentration-time curve from time 0 to 
infinity; Ke: elimination rate constant; T1/2el: elimination half-life; Res. Error: residual error; Vd/F: volume of 
distribution uncorrected for absolute oral bioavailability; Cl/F: total body clearance uncorrected for absolute 
oral bioavailability; T1/2a: absorption half-life; Cmax: maximal plasma concentration; Tmax: time to maximal 
plasma concentration; Tlag: lag time for absorption following oral administration.
−2LL AIC BIC
no EHR 521.72 531.72 539.36
including EHR 518.14 542.13 560.45
Table 4. Comparison of the −2 log likelihood criterion (−2LL), Akaike’s (AIC) and Bayesian information 
criterion (BIC) of the final population models of intravenous meloxicam whether or not including enterohepatic 
recycling (EHR) in the model.
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In the presented study it was not possible to establish dose proportional PK for either mavacoxib, celecoxib as 
meloxicam. However this observation should be taken into account when determining effective dosing regimens.
As a conclusion it can be stated that sensitive and specific LC-MS/MS methods were developed for quantifica-
tion of celecoxib, mavacoxib and meloxicam in avian plasma. Comparison of literature with presented PK param-
eters of meloxicam in cockatiels, such as F and Cl, highlight the presence of interspecies differences. Moreover, 
notable differences were observed in PK of mavacoxib compared to the structurally related celecoxib. As a con-
sequence of lower mavacoxib clearance compared to celecoxib and meloxicam, a less frequent dosing might be 
suggested in cockatiels. However, pharmacodynamic and safety studies are necessary to further investigate the 
use and to establish appropriate dosage regimens of these NSAIDs in cockatiels.
Materials and Methods
Chemicals, products and reagents. The analytical standards of mavacoxib and celecoxib, as well as 
the internal standards (IS) mavacoxib-D4 and celecoxib-D7, were obtained from Clearsynth (Mumbai, India). 
Analytical standard of meloxicam was purchased from Sigma-Aldrich (Bornem, Belgium), whereas meloxi-
cam-13C6 IS was obtained from Alsachim (Illkirch Graffenstaden, France). All analytical standards were stored 
at 2–8 °C. For the analytical experiments, stock solutions (SS) of mavacoxib and celecoxib (50 mg/mL) and their 
IS (5 mg/mL) were prepared in ethanol, whereas SS of meloxicam and meloxicam-13C6 (1 mg/mL) were pre-
pared in methanol. Working solutions (WS) of the standards were prepared by appropriate dilution of the SS. 
All SS and WS were stored at ≤ −15 °C except for meloxicam and its IS which were stored at 2–8 °C. Water and 
acetonitrile (ACN) for analysis of mavacoxib, celecoxib and meloxicam were of HPLC-grade and were obtained 
from Filterservice (Eupen, Belgium). Ammonium acetate, formic acid (FA), ethanol, sodium hydroxide and ethyl 
acetate were of analytical grade and purchased from VWR (Leuven, Belgium). OstroTM protein precipitation and 
phospholipid removal 96-well plates were purchased from Waters (Zellik, Belgium). Microfilters Millex PVDF 
0.22 μm were obtained to filter extracted samples (Millex, Overijse, Belgium).
For celecoxib and mavacoxib only CF for oral applications are available. In order to determine F%, standard 
solutions (STD) were made. STDs (5 mg/mL) were prepared by dissolving the celecoxib and mavacoxib analytical 
standard in a polyethylene glycol (PEG) 400:physiological saline (75:25, v/v) vehicle. This dissolution medium 
was used to overcome the pore water solubility of celecoxib and mavacoxib (logP ≥ 3)21,31. Commercially available 
tablet formulations of celecoxib (Celebrex® 100 mg, Pfizer, Brussels, Belgium) and mavacoxib (Trocoxil® 20 mg, 
Zoetis, Zaventem, Belgium) were ground and lactose was added to obtain a powder mixture with a concentration 
of 10 mg celecoxib/g and 4 mg mavacoxib/g. Immediately prior to oral administration, these powder mixtures 
were mixed with physiological saline (5 mg celecoxib/mL and 2 mg mavacoxib/mL). Since a CF for intravenous 
administration of meloxicam is available in Belgium, no STD for meloxicam was prepared. For IV and PO admin-
istration, respectively Metacam suspension for injection® (5 mg/mL) and Metacam oral suspension® (0.5 mg/mL) 
(Boehringer Ingelheim, Brussels, Belgium) were used.
Animals and experimental procedure. General study design. A group of cockatiels consisting of 90 
birds (45 ♂/45 ♀) of 6–12 months old were group-housed in an aviary during the two week acclimatization 
period at the start of the study, and during wash-out and recovery periods between different experiments. During 
these periods animals were fed with a commercially available seed mixture (Big Parakeets Prestige, Versele-Laga, 
Deinze, Belgium) and water ad libitum. Birds were gender-based randomly allocated to different experimen-
tal groups. Each bird participated in minimum one and maximum two out of the three PK studies. Birds were 
cage-housed in pairs, 8 h prior until 12 h post NSAID administration. In all trials, feed was withheld from 
the birds from 8 h prior until 4 h post NSAID administration. NSAIDs were administered IV (celecoxib and 
mavacoxib STD, meloxicam CF) in the vena cutanea ulnaris superficialis (wing vein) using a 1 mL syringe and 
29 G needle, and PO (celecoxib and mavacoxib STD and CF, meloxicam CF) by intra-crop bolus using a 1 mL 
syringe and a curved stainless steel ball tipped feeding needle. Immediately following IV or PO drug administra-
tion, animals received a 2 mL intra-crop feed bolus (Nutribird A19 High Energy (Versele-Laga):tap water, 25:75, 
v-v) by oral gavage. Subsequently, blood (0.3 mL) was sampled by venipuncture from the jugular vein (vena jug-
ularis) using a 1 mL syringe and 29 G needle, and transferred into heparinized tubes, before (0 h) and at different 
time points after drug administration. A sparse sampling protocol was applied because of the limited volume of 
blood that can be drawn from these birds. Therefore, all sampling points were randomly allocated to different 
birds, with maximum two (celecoxib and meloxicam) or three (mavacoxib) sampling points per bird. After blood 
sampling, all samples were centrifuged (2850 × g, 10 min, 4 °C) within 2 h and aliquots of plasma were stored 
at ≤ −15 °C until analysis.
Celecoxib PK study. The PK characteristics of celecoxib (10 mg/kg BW) were first investigated after a single PO 
administration of celecoxib CF to 22 cockatiels (11♂/11♀, 93 ± 10 g). Besides, celecoxib STD was administered by 
single PO and IV administration in a two-way cross-over design to 34 other cockatiels (17♂/17♀, 91 ± 10 g). For 
the latter, each bird received a single PO bolus of celecoxib STD and an IV bolus of celecoxib STD respecting one 
month of wash-out and recovery period between the two routes of administration. Blood was withdrawn before 
administration (t = 0) and at 15, 30, 45 min, and 1, 2, 4, 6, 8 and 12 h after celecoxib administration. Additional 
sampling was performed 5 min after IV and 24 h after PO administration.
Mavacoxib PK study. After a wash-out and recovery period of one month, the second experiment was con-
ducted to study the PK characteristics of mavacoxib (4 mg/kg BW). A similar setup as for the celecoxib study 
was used. Again a single PO bolus of mavacoxib CF was administered to 26 cockatiels (13♂/13♀, 93 ± 9 g). Next 
IV and PO dosing of celecoxib STD was performed in two-way cross-over design to 40 cockatiels (20♂/20♀, 
101 ± 8 g) with a period of three months wash–out and recovery period between PO and IV STD administrations. 
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Blood was withdrawn before administration (t = 0) and at 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 
168, 336, 672 and 1008 h after administration. An additional sample was taken 5 min after IV administration.
Meloxicam PK study. After a period of six months, the third experiment investigated the PK characteristics of 
meloxicam (1 mg/kg BW) CF in a two-way cross over design in 24 cockatiels (12♂/12♀, weighing 101 ± 12 g), 
with a period of one month between both administrations. Blood was withdrawn before administration (t = 0) 
and at 15, 30, 45 min, and 1, 2, 4, 6, 8 and 12 h following administration. Additional samples were taken 5 min 
after IV and 24 h after PO administration.
Ethics statement. Animal care and all experiments were conducted in accordance with the Belgian Royal Decree 
of 29 may 2013 and the EU directive of 2010/63/EU. The animal experiments were approved by the Ethical 
Committee of the Faculty of Veterinary Medicine and the Faculty of Bioscience Engineering of Ghent University 
(EC 2014/113 and EC 2015/114).
LC-MS/MS analysis of NSAIDs in plasma. Quantification of celecoxib, meloxicam and mavacoxib 
in plasma of cockatiels was carried out using an in-house developed and validated high-performance liquid 
chromatography-tandem mass spectrometry (HPLC-MS/MS) method.
Sample preparation. For cele- and mavacoxib, sample preparation consisted of sequential addition of 25 µL of IS 
WS (1000 ng/mL celecoxib-D7, 200 ng/mL mavacoxib-D4), 25 µL of ethanol, 150 µL of 0.1 M NaOH and 3 mL of 
ethyl acetate to 50 μL of plasma. After vortex mixing (15 s), the samples were extracted for 20 min on a horizontal 
roller mixer and centrifuged for 10 min (3724 × g, 4 °C). The supernatant was evaporated under a gentle nitrogen 
stream (40 ± 5 °C). The dry residue was reconstituted in 250 μL of water/ACN (50:50, v/v). After a vortex-mixing 
step (15 s), the samples were filtered through a Millex® PVDF syringe filter (0.22 µm) and transferred into an 
autosampler vial. A 10 μL aliquot of the final clear solution was injected onto the HPLC-MS/MS instrument.
Sample preparation for meloxicam consisted of the addition of 50 µL of HPLC methanol and 25 µL of IS WS 
(10 µg/mL) 13C6-meloxicam to 50 μL of plasma. After vortex mixing, the plasma samples were transferred to an 
OstroTM 96-well plate, followed by the addition of 375 µL of 1% FA in ACN to each well. After aspirating the sam-
ples 5 times using a multichannel pipette, the sample was passed through the well plate by application of a vacuum 
for 5–10 min. A 10 μL aliquot was injected onto the HPLC-MS/MS instrument.
LC-MS/MS instrumentation. Chromatographic separation was achieved on a Zorbax Eclipse plus C18 column 
(3.0 mm internal diameter × 100 mm, particle diameter, 3.5 μm) in combination with a guard column of the 
same type, both from Agilent Technologies (Sint-Katelijne-Waver, Belgium). The mobile phases for cele- and 
mavacoxib analysis consisted of 10 mM ammonium acetate in HPLC grade water (mobile phase A) and HPLC 
grade ACN (mobile phase B). Following gradient elution program was run: 0.0–1.0 min (50% A, 50% B), 1.0–
6.0 min (linear gradient to 90% B), 6.0–8.5 min (10% A, 90% B), 8.5–9.0 min (linear gradient to 50% A), and 
9.0–12.0 min (50% A, 50% B). Flow rate was set at 300 μL/min. For meloxicam, HPLC grade water containing 
0.01% formic acid (mobile phase A) and HPLC grade ACN containing 0.01% formic acid (mobile phase B) were 
used. Following gradient elution program was run: 0.0–1.5 min (60% A, 40% B), 1.5–5.20 min (linear gradient to 
5% A), 5.2–7.0 min (5% A, 95% B), 7.0–7.1 min (linear gradient to 40% B) and 7.1–10 min (60% A, 40% B). Flow 
rate was set at 300 µL/min.
Detection was performed on a TSQ Quantum Ultra triple-quadrupole mass spectrometer (ThermoFisher 
Scientific, Breda, the Netherlands), equipped with a heated electrospray ionization (h-ESI) probe operat-
ing in the negative ionization mode for celecoxib and mavacoxib, and in the positive ionization mode for 
meloxicam. Following transitions (m/z) were used for identification and quantification, respectively, for cel-
ecoxib: 380.1 → 316.1 and 380.1 → 276.0, for celecoxib-D7: 387.1 → 323.1 and 387.1 → 283.0, for mavacoxib: 
384.1 → 320.0 and 384.1 → 279.9, for mavacoxib-D4: 388.1 → 283.1 and 388.1 → 324.1, for meloxicam: 
352.0 → 115.0 and 352.0 → 141.0, and for meloxicam-13C6: 358.0 → 115.0 and 358.0 → 141.0.
The methods were validated in house according to recommendations reported in literature and guidelines of 
the European Community40–43. Based on the limited blood volume of cockatiels, LC-MS/MS calibration and vali-
dation were performed using broiler chicken plasma. Following parameters were evaluated: linearity (r and gof), 
within-run and between-run precision and accuracy, LOQ, LOD and carry-over. The validation protocol and the 
acceptance criteria used were previously described by De Baere et al.44.
Plasma protein binding. Freshly blank cockatiel plasma was spiked with celecoxib, mavacoxib or meloxi-
cam STD at 0.50 µg/ mL and 5.0 µg/mL. One aliquot of each concentration was analysed in the same way as the 
PK study samples (aliquot 1) to determine the total plasma concentration. Two other aliquots of each concentra-
tion (aliquot 2 and 3) were incubated for 1 hour in a hot water bath of 41 °C, and subsequently transferred onto 
Microcon® centrifugal filters (type Ultracel YM-30, Merck, Overijse, Belgium) and centrifuged (2980 × g, 10 min, 
41 °C). Thereafter, the obtained filtrate of aliquot 2 and 3 were analysed in the same way as the PK study samples 
to determine the free plasma concentration. For quantification, corresponding calibration curves for each aliquot 
were used. Equation (1) was used to calculate the plasma protein binding.
=
. − .
.
×Plasma protein binding total plasma conc free plasma conc
total plasma conc
(%) ( ) 100
(1)
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The results are presented as mean ± standard deviation.
Pharmacokinetic analysis. Population pharmacokinetics celecoxib. Plasma concentration–time data 
were analysed by nonlinear mixed-effects regression using first-order conditional estimation with extended least 
squares (FOCE-ELS) as an estimation method in Phoenix NLME® (Certara, Cary, NC, USA). Values below the 
LOQ were excluded from the data set prior to data summarization and pharmacokinetic analysis. The structural 
PK model for the IV data was a one-compartment model with first order elimination as expressed by equation (2).
= . −C t C e( ) (2)
Cl
Vd
t
0
Where C is the plasma concentration, t is the time, Cl is total body clearance, Vd is the volume of distribution 
and C0 is the concentration at time zero. The structural model for the PO data (celecoxib STD and CF) was a 
one-compartmental with first order absorption and elimination as expressed by equation (3). A lag time for 
absorption (Tlag) was considered for each PO model.
=
−
⋅ −− −C t F D k
Vd k k
e e( )
( )
( )
(3)
a
a e
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Where F denotes the bioavailability, ka is the first-order absorption rate constant, ke is the first-order elimina-
tion rate constant and D is the dose. Interindividual variability was expressed using an exponential error model 
according to equation (4).
= θ ⋅ ηP e (4)i iP P
where Pi is the primary pharmacokinetic parameter value in the ith patient, θP is the typical value of the param-
eter in the population, and ηPi is a random variable in the ith patient with a mean of zero and a variance of ω². 
Interindividual variability is reported as ω. Residual variability (ε), with a mean of zero and a variance of σ², was 
evaluated within the best structural PK model. For the IV and PO STD dosing, a multiplicative (equation (5)) and 
additive (equation (6)) error model was used to describe the residual variability, respectively, whereas for the PO 
CF administration, the best residual error model was log-additive (equation (7)).
ε= ⋅ +C CMultiplicative: (1 ) (5)obs pred
ε= +C CAdditive: (6)obs pred
‐ ( )C C sqrt CLog additive: 1 (7)obs pred pred2 ( /mult add)2ε= + ⋅ + σ σ⋅
Where σmult is the variance of the multiplicative residual error; σadd is the variance of the additive residual error; 
Cobs is the observed concentration for the individual; Cpred is the model predicted concentration and ε is the error 
value.
Structural and error model selection was guided by visual inspection of goodness-of-fit plots (e.g., observed 
vs. predicted plasma concentrations, weighted residuals versus predicted concentrations, and weighted residuals 
versus time), −2LL, AIC and BIC as well as precision of the parameter estimates. The models were chosen based 
on the smaller values of −2LL, AIC and BIC, better precision of estimates, and superior goodness-of-fit plots.
Evaluated covariates were BW (continuous variable) and gender (categorical variable). A stepwise 
forward-backward process was used to evaluate whether inclusion of the covariates significantly improved the 
model fit using a −2LL test. A decrease in −2LL with a p-value < 0.01 was considered significant for addition and 
p < 0.001 for exclusion of the covariate.
Following fixed effect parameters were determined: Vd: volume of distribution (IV); Vd/F: volume of distri-
bution uncorrected for absolute oral bioavailability (PO); Cl: total body clearance (IV); Cl/F: total body clearance 
uncorrected for absolute oral bioavailability (PO); Ka: absorption rate constant and Tlag: lag time for absorption 
following oral administration. Computed secondary parameters were: C0: plasma concentration at time 0 follow-
ing IV administration; AUC0-inf: area under the plasma concentration-time curve from time 0 to infinity; Ke: elim-
ination rate constant; T1/2el: elimination half-life; T1/2a: absorption half-life; Cmax: maximal plasma concentration; 
Tmax: time to maximal plasma concentration; K1g: bile excretion rate and τ: bile excretion interval.
The absolute oral bioavailability (F, expressed as %, F%) was calculated according to equation (8).
‐ ‐= ×F% AUC /AUC 100 (8)0 inf PO 0 inf IV
Where AUC0-inf is area under the plasma concentration-time curve from time 0 to infinity.
Population pharmacokinetics mavacoxib. PopPK analysis for mavacoxib was performed in a similar manner as 
for celecoxib. The structural PK model for the IV (STD) and PO (STD/CF) data was a one-compartment model 
with first order elimination and a one-compartment with first order absorption and elimination, respectively. 
Inter- and intra-individual variability were expressed according to the exponential error model and the multi-
plicative residual error model, respectively. Selection and validation of the models and covariate evaluation was 
performed as described above.
www.nature.com/scientificreports/
1 1SCIenTIFIC RePoRTS | 7: 12043  | DOI:10.1038/s41598-017-12159-z
Population pharmacokinetics meloxicam. Visual inspection of the plasma concentration-time profiles revealed 
a secondary rise in the average plasma concentration during the elimination phase (around 1-2 and 4 h fol-
lowing IV and PO administration, respectively) following both IV and PO administration of meloxicam. This 
could be attributable to EHR, which has previously been described for meloxicam33. Therefore, for the IV data a 
one-compartment structural model with first order elimination was compared with or without the inclusion of 
EHR. This model was derived from Gabrielsson and Weiner45. Also for PO administration, a one-compartment 
model with a lag time, first order absorption and first order elimination was compared with and without EHR 
inclusion. Inter- and intra-individual variability were expressed according to the exponential error model and the 
multiplicative residual error model, respectively. Comparison and selection of the models and covariate evalua-
tion was performed as described above.
Data Availability. The datasets generated and/or analysed during the current study are available from the 
corresponding author on reasonable request.
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